Psychosocial Effects of a Trauma-Informed Artificial Intelligence-Supported Chatbot in Adults Newly Diagnosed With Cancer
Evaluation of the Psychosocial Effects of a Trauma-Informed Care-Based Artificial Intelligence-Supported Chatbot in Newly Diagnosed Cancer Patients: A Randomized Controlled Trial
The goal of this clinical trial is to evaluate whether a trauma-informed, artificial intelligence-supported chatbot can reduce psychological distress and unmet psychosocial needs in adults newly diagnosed with cancer.:
- Does the chatbot reduce trauma-related distress and anxiety levels compared to standard care?
- Does the chatbot decrease unmet psychosocial needs in patients following a new cancer diagnosis? Researchers will compare the chatbot intervention to standard care to determine whether the chatbot provides additional psychosocial benefit.
Participants will:
- Be randomly assigned to either the chatbot intervention group or the standard care group
- Use the chatbot freely for 12 weeks (intervention group only)
- Complete questionnaires at baseline, 1 month, and 3 months
- Be monitored for any psychological risk indicators during the study period
Studieöversikt
Status
Intervention / Behandling
Detaljerad beskrivning
Receiving a cancer diagnosis is a potentially traumatic experience associated with significant psychological distress, anxiety, and unmet psychosocial needs. Despite the recognized importance of psychosocial care in oncology, barriers such as limited healthcare resources, heavy workload, and insufficient access to timely support may prevent patients from receiving adequate psychosocial interventions during the early stages following diagnosis.
Trauma-Informed Care (TIC) is an approach that recognizes the psychological impact of traumatic experiences and aims to provide support through principles including safety, trustworthiness, empowerment, collaboration, and cultural sensitivity. Integrating TIC principles into digital health interventions may provide accessible and individualized psychosocial support for patients newly diagnosed with cancer.
This study aims to evaluate the effectiveness of a trauma-informed, artificial intelligence-supported chatbot developed to provide early psychosocial support to adults newly diagnosed with cancer. The chatbot is designed to deliver empathetic and supportive interactions grounded in trauma-informed care principles. It provides psycho-education, emotional support, coping facilitation, and guidance toward professional support resources when needed, without offering medical diagnosis or treatment recommendations.
The study is designed as a randomized controlled trial consisting of an intervention group receiving access to the chatbot in addition to standard care and a control group receiving standard care alone. Outcomes related to trauma-related distress, anxiety and psychosocial needs will be evaluated over a 12-week period.
The chatbot system incorporates predefined safety mechanisms and interaction-based monitoring to identify potential psychological risk indicators during use. Participants identified as potentially at risk may be directed toward appropriate professional support resources according to the study safety protocol.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Nevra Didem Kılınç, PhD(c)
- Telefonnummer: +9 0539 436 53 17
- E-post: nozluk23@ku.edu.tr
Studera Kontakt Backup
- Namn: Fahriye Oflaz, Professor
- Telefonnummer: +905445452725
- E-post: foflaz@ku.edu.tr
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Over 18 years of age,
- Able to speak and understand Turkish,
- Without any cognitive, visual, or auditory impairments,
- Diagnosed with cancer within the last month (Stage I, II, and III) (regardless of cancer type),
- Have started active cancer treatment,
- Have access to a digital device and the internet,
- Volunteer to participate in the study will be included.
Exclusion Criteria:
- Patients participating in another simultaneous psychosocial/digital intervention study,
- Patients diagnosed with advanced stage (Stage IV) cancer, in the terminal phase and with metastases,
- Patients diagnosed with schizophrenia, bipolar disorder, substance abuse, depression and anxiety disorders will be excluded.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Stödjande vård
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Chatbot
Participants in this arm will receive access to a trauma-informed, artificial intelligence-supported chatbot designed to provide psychosocial support following a new cancer diagnosis.
The chatbot allows free-text interaction and is available for use over a 12-week period.
It is designed in line with trauma-informed care principles and provides emotional support, coping facilitation, and guidance toward professional help when needed.
Participants will also receive standard care.
Chatbot interactions will be monitored for potential psychological risk indicators, and appropriate guidance will be provided if risk is detected.
|
The intervention consists of a trauma-informed, AI-supported chatbot designed to provide psychosocial support to adults newly diagnosed with cancer.
The chatbot is grounded in trauma-informed care principles, including safety, trustworthiness, empowerment, collaboration, and sensitivity to emotional distress following diagnosis.
It enables free-text, user-initiated conversations and delivers empathetic, non-directive support aimed at facilitating emotional expression, coping, and adaptation to diagnosis.
The chatbot does not provide medical, pharmacological, nutritional, or exercise advice.
Instead, it focuses on psychosocial support and encourages users to seek professional help when appropriate.
The system incorporates predefined safety rules and continuous interaction-based risk monitoring; when indicators of psychological risk are detected, users are guided toward appropriate support resources.
Participants are granted access to the chatbot for a 12-week period.
|
|
Inget ingripande: Control
Participants in this arm will receive standard care as routinely provided by the institution.
No chatbot intervention will be provided during the study period.
Participants may access usual psychosocial or clinical support services as needed
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Trauma-related distress
Tidsram: Baseline, 1 and 3 months
|
Trauma-related distress associated with cancer diagnosis will be assessed using the Impact of Event Scale-Revised (IES-R).
The IES-R is a validated self-report instrument measuring intrusion, avoidance, and hyperarousal symptoms.
Total scores range from 0 to 88, with higher scores indicating greater trauma-related distress.
|
Baseline, 1 and 3 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Anxiety levels
Tidsram: Baseline, 1 and 3 months
|
Anxiety will be measured using the State-Trait Anxiety Inventory (STAI), which assesses both state and trait anxiety levels.
Scores for each sub-scale range from 20 to 80, with higher scores indicating higher anxiety levels.
|
Baseline, 1 and 3 months
|
|
Unmet psychosocial needs
Tidsram: Baseline, 1 and 3 months
|
Psychosocial needs will be assessed using the Psychosocial Needs Inventory (PNI), a 48-item scale evaluating the importance and fulfillment of psychosocial needs across multiple domains.
Items are scored on a 1-5 Likert scale.
Higher scores indicate greater perceived importance and/or better fulfillment of psychosocial needs.
|
Baseline, 1 and 3 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Nevra Didem Kılınç, PhD(c), Koc University
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025.468.IRB3.232
- 325S436 (Annat bidrag/finansieringsnummer: TÜBİTAK)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .